Sana Biotechnology: UP421 12 haftalık NEJM verileri HIP adacık hücrelerinin T1D'de hayatta kaldığını ve işlev gördüğünü gösteriyor

Kaynak alıntısı

EX-99.1 2 sana-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Sana Biotechnology Reports Third Quarter 2025 Financial Results and Business Updates Announced increased focus on type 1 diabetes and in vivo CAR T programs Regulatory interactions increase confidence in moving forward with GMP master cell bank for SC451, nonclinical testing plan, and path to filing SC451 Investigational New Drug Application (IND) as early as 2026 The New England Journal of Medicine published positive 12-week clinical results of ongoing type 1 diabetes study with UP421, which demonstrate that Sana’s hypoimmune-modified pancreatic islet cells are safe and well-tolerated, survive, evade detection by the immune system, and produce insulin in the patient Next-generation in vivo CAR T product candidate, SG293, demonstr

SEC 8-K

Bu varlık hakkında daha fazlası

Dikkate değer

10 Ağu 2026

20:09

SANASana Biotechnology

Sana Biotechnology: UP421 verileri EASD 2026'da 2 Ekim'de

Konferans sunumuSEC 8-K

Dikkate değer

14 Oca 2026

17:45

SANASana Biotechnology

Sana Biotechnology 2026 hedefleri: SC451 IND başvurusu ve SG293 ilk-insan verileri

DiğerSEC 8-K